Showing results (41-50 of 48) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.Nature Medicine|June 7, 2026
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trialLee M Kaplan, Elena Startseva, Carel W le Roux, et al.Lancet (London, England)|August 16, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialMazen Noureddin, Juan P Frias, Guy W Neff, et al.Journal of Hepatology|June 10, 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisEric J Lawitz, Mandy Fraessdorf, Guy W Neff, et al.The New England Journal of Medicine|May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASHMazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.Journal of Hepatology|April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisChristopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.The New England Journal of Medicine|February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver FibrosisStephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.Pageof 5